Our Pricing

Wegovy Dosing: Complete UK Clinical Guide to Safe Dose Escalation

Understanding wegovy dosing is essential for achieving optimal weight loss outcomes while minimising side effects. Wegovy (semaglutide 2.4mg) follows a structured dose escalation protocol over 16-20 weeks, starting at 0.25mg weekly and gradually increasing to the maintenance dose of 2.4mg once weekly. This gradual titration schedule, validated in the STEP clinical trial programme, significantly improves gastrointestinal tolerability whilst allowing your body to adapt to the medication's appetite-suppressing effects [1].

Wegovy Dosing Schedule: The Complete UK Escalation Protocol

The wegovy dosing schedule is designed as a five-stage escalation protocol, each lasting four weeks. You begin with 0.25mg subcutaneously once weekly for the first month, then progress to 0.5mg for weeks 5-8, followed by 1mg for weeks 9-12, then 1.7mg for weeks 13-16, and finally reach the maintenance dose of 2.4mg from week 17 onwards [1]. This gradual increase allows your gastrointestinal system to adapt to semaglutide's effects on gastric emptying and appetite regulation.

Clinical data from the STEP trials demonstrated that patients following this structured wegovy dosing protocol experienced 68% fewer treatment discontinuations due to gastrointestinal adverse events compared to rapid escalation approaches [2]. Each dose increase should occur only if you've tolerated the current dose for the full four-week period. If you experience persistent nausea, vomiting, or diarrhoea, your prescriber may recommend remaining at your current dose for an additional four weeks before escalating further.

At Cured Pharmacy, our UK-registered clinical team provides ongoing dosing support throughout your treatment journey. All wegovy dosing adjustments require clinical assessment by a qualified prescriber, ensuring your escalation schedule aligns with your individual tolerance and weight loss progress. Subject to prescriber approval, you can access Wegovy from £69.00, with transparent pricing displayed before your consultation.

Understanding Wegovy Dosing: Why Gradual Escalation Matters

The rationale behind wegovy dosing escalation lies in semaglutide's mechanism of action as a GLP-1 receptor agonist. Semaglutide slows gastric emptying, increases satiety signalling to the brain, and reduces appetite through hypothalamic pathways [3]. Introducing these effects gradually allows your digestive system to adapt, significantly reducing the incidence and severity of nausea, the most commonly reported side effect.

Research indicates that approximately 44% of patients experience some degree of nausea when starting GLP-1 therapy, but this drops to under 20% by the maintenance phase when proper wegovy dosing escalation is followed [2]. The four-week intervals between dose increases allow sufficient time for neuroadaptation in appetite centres and gastrointestinal accommodation to delayed emptying patterns.

What Happens If You Miss a Wegovy Dose?

If you miss a scheduled wegovy dosing injection, the guidance depends on timing. If fewer than five days have passed since your missed dose, administer it as soon as you remember, then resume your regular weekly schedule. However, if more than five days have elapsed, skip the missed dose entirely and take your next injection on your regularly scheduled day [4]. Never double up doses to compensate for a missed injection, as this significantly increases the risk of severe gastrointestinal side effects and does not improve weight loss outcomes.

Wegovy Dosing Administration: Injection Technique and Timing

Proper wegovy dosing technique involves subcutaneous injection into the abdomen, thigh, or upper arm using the pre-filled single-dose pen. The medication should be injected once weekly on the same day each week, though the time of day can vary based on your preference. Clinical trials showed no significant difference in efficacy or tolerability whether Wegovy was administered in the morning, afternoon, or evening [1].

Rotate your injection sites with each dose to minimise the risk of lipohypertrophy (fatty lumps under the skin). The abdomen typically offers the most consistent absorption, though thigh and upper arm sites are equally effective when used correctly. Always inspect the solution before injection—it should be clear and colourless. Do not use the pen if the solution appears cloudy, discoloured, or contains particles.

Store unopened Wegovy pens in the refrigerator at 2-8°C. Once in use, pens can be kept at room temperature (below 30°C) or refrigerated for up to 28 days. Never freeze Wegovy, and discard any pen that has been frozen. Our pharmacists at Cured Pharmacy provide detailed injection training resources with every prescription, ensuring you're confident with your wegovy dosing technique from day one.

Can You Adjust Your Wegovy Dosing Day?

Yes, you can change your regular wegovy dosing day if needed, provided at least two days (48 hours) pass between injections. For example, if you normally inject on Monday but need to switch to Friday, you can do so as long as your last Monday injection was at least 48 hours prior. Once you've administered the dose on your new day, continue weekly injections on that day going forward. Always consult your prescriber before making scheduling changes to ensure proper guidance.

Wegovy Dosing and Weight Loss: Expected Results by Dose

Weight loss outcomes correlate directly with wegovy dosing levels. In the STEP 1 trial, participants achieved an average of 5.9% body weight reduction by week 20 (when reaching the 1.7mg dose), increasing to 14.9% total body weight loss by week 68 on the 2.4mg maintenance dose [1]. The majority of weight loss occurs during the escalation phase and first six months at maintenance dosing, with weight stabilisation typically occurring between months 8-12.

It's important to note that weight loss is not linear throughout the wegovy dosing schedule. Many patients experience minimal weight reduction during the initial 0.25mg and 0.5mg doses, with more significant losses beginning at the 1mg dose and accelerating at 1.7mg and 2.4mg. This pattern reflects the dose-dependent nature of semaglutide's appetite suppression and metabolic effects [3].

Individual responses to wegovy dosing vary considerably based on baseline BMI, adherence to lifestyle modifications, metabolic factors, and genetic variations in GLP-1 receptor expression. Approximately 86% of patients achieve at least 5% body weight loss on the full 2.4mg dose, whilst 50% achieve 15% or greater weight reduction [1]. These outcomes require consistent weekly dosing combined with a reduced-calorie diet and increased physical activity.

Managing Side Effects During Wegovy Dosing Escalation

The most common side effects during wegovy dosing escalation are gastrointestinal: nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%) [2]. These effects typically peak 1-3 days after each dose increase and diminish over the subsequent 2-3 weeks as your body adapts. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce symptom severity.

If side effects become intolerable at any wegovy dosing level, do not independently reduce your dose. Contact your prescriber to discuss whether maintaining your current dose for an additional four weeks or temporarily reducing to the previous dose level is appropriate. Abrupt dose reductions without clinical guidance can disrupt your weight loss trajectory and may require restarting the escalation protocol.

Serious side effects, though rare, require immediate medical attention. These include severe abdominal pain (potential pancreatitis), persistent vomiting leading to dehydration, visual changes, or signs of thyroid tumours (neck lump, hoarseness, difficulty swallowing). Our clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), provides ongoing monitoring support throughout your wegovy dosing journey, with same-day clinical advice available when concerns arise.

When to Pause Wegovy Dosing

Temporarily discontinuing wegovy dosing may be necessary before planned surgeries or medical procedures, particularly those involving general anaesthesia, due to the medication's effects on gastric emptying. Your surgeon or anaesthetist will advise on the appropriate cessation period, typically 1-2 weeks pre-operatively. Similarly, if you develop acute pancreatitis, severe gastrointestinal symptoms, or become pregnant, wegovy dosing must be stopped immediately under medical supervision. Always consult your prescriber before pausing or restarting treatment.

Wegovy Dosing Cost and Access Through Cured Pharmacy

Understanding wegovy dosing costs is essential for treatment planning, as this is a long-term commitment requiring consistent monthly prescriptions. At Cured Pharmacy, Wegovy is available from £69.00, representing competitive UK pricing with transparent costs displayed before your online consultation. New patients receive £20 off their first order using code Weightlossnew, bringing the initial cost to £69.00.

All wegovy dosing prescriptions require clinical assessment by a UK-registered prescriber through our streamlined online consultation platform, typically completed in under three minutes. Our clinical team evaluates your BMI, weight loss history, contraindications, and current medications to determine suitability for Wegovy therapy. Subject to prescriber approval, your medication is dispensed by our GPhC-registered pharmacy (9012511) with discreet next-day delivery throughout the UK.

We supply only genuine, UK-licensed Wegovy manufactured by Novo Nordisk, ensuring you receive authentic medication with proper storage and handling throughout the supply chain. Each prescription includes comprehensive wegovy dosing guidance, injection technique instructions, and access to our clinical support team for any questions during your treatment journey. Ongoing prescriptions require periodic clinical reviews to monitor progress, side effects, and continued appropriateness of therapy.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425.
3. Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., ... & Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130.
4. Novo Nordisk. (2023). Wegovy (semaglutide) injection 2.4 mg: Prescribing Information. Novo Nordisk A/S.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.